Form 4 Filing for MoonLake Immunotherapeutics

This filing details transactions made by Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics. On July 21, 2026, Reich sold 50,000 shares of Class A ordinary shares at a weighted average price of $20.02 per share, with individual sales ranging from $20.00 to $20.06. This was executed under a Rule 10b5-1 trading plan. Following this transaction, Reich beneficially owned 2,714,746 shares. On July 22, 2026, an additional 2,448 shares were sold at $20.00 per share, resulting in 2,712,298 shares owned post-transaction. Some shares sold are indirectly owned through JeruCON Beratungsgesellschaft mbH, as noted in footnote F3.